WeChat

 

Achievements

  • Ningshao Xia:Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial

    2024-04-09
  • Ningshao Xia: Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters

    2023-09-22
  • Ningshao Xia: Anti–Epstein–Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer

    2023-09-22